Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][3] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise no more than 2 billion yuan, with the funds primarily directed towards the development of an AI research platform [1][2] - The strategic investor, Yangshengtang, is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [1] Group 2 - The funds raised will focus on the "Humanized Collagen FAST Database and Product Development Platform Project," which utilizes the company's self-developed "AI Collagen Brain System" technology to enhance efficiency in the development of humanized collagen [2] - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, with the current focus on targeted convertible bonds and stock issuance, as evidenced by Jinbo Bio's successful registration [3] - The successful implementation of Jinbo Bio's stock issuance is expected to increase overall market attention on companies listed on the Beijing Stock Exchange, attracting various long-term funds and enhancing market liquidity [4]
时隔两年北交所定增“破冰”锦波生物20亿元再融资获批